Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Agreement with Ilara Health to sell ResAppDx in Kenya

05/03/2021 | 04:27pm EDT

ResApp Health Limited announced that health technology company Ilara Health will promote, market and sell ResAppDx, ResApp's smartphone app for acute respiratory disease. Ilara Health powers existing primary care facilities with next-generation point of care diagnostic tools to bridge the diagnostic gap across sub-Saharan Africa. Ilara are currently partnered with over 250 clinics across the four large cities in Kenya and will look to expand across the wide country and a new African market within the next 12 months. R esAppDx is ResApp's acute respiratory diagnostic test that uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. It is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia. ResAppDx is also approved as a medical device in Kenya.


ę S&P Capital IQ 2021
All news about RESAPP HEALTH LIMITED
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
MT
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
PU
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
MT
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
PU
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
CI
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
MT
08/31RESAPP HEALTH : ResAppDx receives regulatory approval in Indonesia
PU
08/31ResApp Health Limited Receives Regulatory Approval in Indonesia
CI
08/26ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/26ResApp Health Limited Auditor Raises 'Going Concern' Doubt
CI
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,92 M -4,92 M
Net cash 2021 6,40 M 4,64 M 4,64 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 64,4 M 46,7 M 46,8 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 84,4%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-11.76%48
SNAP INC.58.52%126 265
ANGI INC.4.89%6 978
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-45.73%4 886
CONTEXTLOGIC INC.-66.37%3 853